Loading
A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by HotSpot Therapeutics, Inc, active and no longer recruiting.
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody is a phase 1/2 interventional study registered as NCT05662397 by HotSpot Therapeutics, Inc, with 77 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: HST-1011 and Cemiplimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cemiplimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cemiplimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cemiplimab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/